Using fluorescent-labeled IgG to improve liver tumor detection during surgery
Intraoperative Liver Tumor Imaging Using Fluorescent-labeled Human IgG
This study is testing a special fluorescent dye to see if it can help doctors find liver tumors more easily during surgery for patients who need liver surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Chinese Academy of Sciences Government |
| Locations | 1 site (Luzhou, Sichuan) |
| Trial ID | NCT05394246 on ClinicalTrials.gov |
What this trial studies
This study evaluates the use of a fluorescent-labeled IgG probe, known as FluoAB, to enhance the detection of liver tumors during surgical procedures. The primary goals are to validate the safety and effectiveness of FluoAB in hepatic surgery and to improve surgical precision through fluorescence imaging. Patients diagnosed with liver tumors who are scheduled for hepatectomy will be monitored to assess the benefits of this imaging technique in distinguishing tumors from surrounding liver tissue affected by cirrhosis.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with liver tumors who are planned to undergo hepatectomy and have Child-Pugh A/B liver function.
Not a fit: Patients with metastatic lesions, severe organ dysfunction, or those unable to tolerate surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the accuracy of liver tumor detection during surgery, leading to better surgical outcomes.
How similar studies have performed: While the use of fluorescence imaging in surgery is gaining traction, this specific application of fluorescent-labeled IgG for liver tumors is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who have been diagnosed with liver tumor. 2. Planned to receive hepatectomy. 3. Liver function Child-Pugh A/B. 4. The expected lifetime is longer than 6 months. 5. Approved to sign the informed consent. Exclusion Criteria: 1. Enrolled in other trials in the past 3 months. 2. Metastatic lesions were found. 3. Undesirable function of heart, lung, kidney, or any other organs. 4. Unable to tolerate a hepatectomy. 5. The researchers considered inappropriate to be included.
Where this trial is running
Luzhou, Sichuan
- The Affiliated Hospital of Southwest Medical University — Luzhou, Sichuan, China (Recruiting)
Study contacts
- Principal investigator: Bo Li, MD. — The Affiliated Hospital Of Southwest Medical University
- Study coordinator: Zeyu Zhang, Ph.D.
- Email: zhangzeyu@fingerpass.net.cn
- Phone: 86-18201082715
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.